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Abstract
The use of hydroxyurea (HU) can improve the clinical course of sickle
cell disease. However, several features of HU treatment remain unclear,
including the predictability of drug response and determination of
adequate doses, considering positive responses and minimal side ef-
fects. In order to identify adequate doses of HU for treatment of sickle
cell disease, 10 patients, 8 with sickle cell anemia and 2 with Sß
thalassemia (8SS, 2Sß), were studied for a period of 6 to 19 months in
an open label dose escalation trial (10 to 20 mg kg-1 day-1). Hemoglobin
(Hb), fetal hemoglobin (Hb F) and mean corpuscular volume (MCV)
values and reticulocyte, neutrophil and platelet counts were performed
every two weeks during the increase of the HU dose and every 4 weeks
when the maximum HU dose was established. Reduction in the number
of vasoocclusive episodes was also considered in order to evaluate the
efficiency of the treatment. The final Hb and Hb F concentrations, and
MCV values were significantly higher than the initial values, while the
final reticulocyte and neutrophil counts were significantly lower. There
was an improvement in the concentration of Hb (range: 0.7-2.0 g/dl) at
15 mg HU kg-1 day-1, but this concentration did not increase significant-
ly when the HU dose was raised to 20 mg kg-1 day-1. The concentration
of Hb F increased significantly (range: 1.0-18.1%) when 15 mg HU was
used, and continued to increase when the dose was raised to 20 mg kg-1
day-1. The final MCV values increased 11-28 fl (femtoliters). However,
reticulocyte (range: 51-205 x 109/l) and neutrophil counts (range:
9.5-1.3 x 109/l) obtained at this dose were significantly lower than those
obtained with 15 mg kg-1 day-1. All patients reported a decrease in
frequency or severity of vasoocclusive episodes. These results suggest
that a hydroxyurea dose of 15 mg kg-1 day-1 seems to be adequate for
treatment of sickle cell disease in view of the minimal side effects
observed and the improvement in laboratory and clinical parameters.
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Introduction
Sickle cell disease is the most common
severe hemoglobinopathy. Despite the years
of intensive research, there is no effective
primary therapy available for these patients,
who experience all the problems associated
with a painful and chronic disease. For most
patients, treatment is limited to a supportive
environment, management of complications
and pain crises, and to the detection of signs
which may predict early morbidity or mor-
tality. The development of primary therapies
for sickle cell disease has received special
attention, particularly those involved in the
prevention or reversal of the polymerization
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of sickle hemoglobin (Hb S) in erythrocytes
(1-3). The most encouraging approach to
prevent Hb S polymerization has been the
use of pharmacological agents which in-
crease the production of fetal hemoglobin
(Hb F) (1-6). Hydroxyurea (HU) induces Hb
F synthesis (1,4-12) and can increase hemo-
globin (Hb) concentration and mean corpus-
cular volume (MCV) in sickle cell disease
(1,4,5,7,13,14). A decrease in frequency and
severity of vasoocclusive episodes has been
reported, suggesting a less severe course of
the disease during drug administration (4,5,
7,12).
However, many questions remain unan-
swered, such as which factors determine the
increase in Hb and Hb F concentrations and
in MCV values, whether these findings will
eventually lead to a significant clinical im-
provement and which doses of HU are ad-
equate for each patient, where positive re-
sponses and minimal side effects are consid-
ered. The range of optimal HU doses for obtain-
ing the desired hematological and clinical
effects is not known since most studies em-
ployed the maximum doses of HU tolerated.
In order to evaluate the adequacy of low
doses of HU in the treatment of sickle cell
disease, an open label dose escalation trial
was undertaken, and three different doses of
HU (10, 15, and 20 mg kg-1 day-1) were com-
pared.
Patients and Methods
The following protocol was approved by
the Hospital Ethics Committee and oral in-
formed consent was obtained from the pa-
tients.
Eligibility requirements
Ten adult patients (18 years old or more)
with sickle cell anemia or Sß thalassemia
(8SS and 2Sß) seen at the University Hospi-
tal of Campinas and fulfilling one or more of
the following criteria were eligible for the
study: 1) at least three severe painful crises
during the year before entering the study
(including emergency room visits), 2) Hb
concentrations lower than 6 g/dl, 3) pro-
longed priapism episodes (for more than 12
h), 4) previous cerebral vascular accident
(CVA) and alloimmunization, and 5) chronic
extensive leg ulcers. Two of the patients had
had a stroke during childhood and had been
receiving transfusion for at least ten years.
Both developed alloimmunization and for
one of them access to the vein for transfusion
became difficult. The diagnosis of sickle cell
disease was confirmed by hemoglobin elec-
trophoresis performed on an acetate cellu-
lose membrane, pH 8.6, and citrate agar gel,
pH 6.2, and in most cases by family studies.
Hb A2 was eluted for quantification (15). Hb
F concentration was determined using the
method of Singer with modifications (16).
Globin gene haplotypes were determined as
described elsewhere (17). Patients with as-
partate aminotransferase (AST) or alanine
aminotransferase (ALT) higher than 100 IU/
l and creatinine higher than 1 mg/dl or crea-
tinine clearance lower than 100 ml min-1
1.73 m-2 were excluded from the study.
Drug doses
The initial dose of HU (Bristol, Regens-
burg, Germany) was 10 mg kg-1 day-1, given
once a day, and was increased by 5 mg kg-1
day-1 every 8 weeks, unless toxicity was
present, to a maximum dose of 20 mg kg-1
day-1. Toxicity was defined by the presence
of at least one of the following characteris-
tics: reticulocytes <50 x 109/l, neutrophils
<2 x 109/l, platelets <100 x 109/l, a 20%
decrease in Hb concentration or an absolute
value of less than 4.5 g/dl, a 50% increase in
serum creatinine or a 100% increase in AST
or ALT.
Laboratory studies
Basal peripheral blood cell counts were
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obtained at the beginning of the study, every
2 weeks during the increase of the drug
dosage and every 4 weeks after the maxi-
mum HU dose was established. Hb concen-
tration, MCV values and platelet counts were
obtained with an automated instrument (Cell-
Dyn, Model 1600 CS). The neutrophil and
reticulocyte counts were obtained manually.
AST and ALT were determined using a
Boehringer kit (Mannheim, Germany) and a
Merck kit (Darmstadt, Germany) was used
for the determination of urea and creatinine
values. All these parameters were measured
every 4 weeks and the mean values were
determined for different HU doses (10, 15
and 20 mg kg-1 day-1). Hb F concentrations
were also evaluated according to gender and
haplotype of sickle cell disease.
Clinical parameters
The frequency of severe painful crises
for each patient was determined during the
administration of HU and during an equal
period immediately before HU administra-
tion and is reported as annual frequency
computed by dividing the number of crises
by the number of years elapsed. A crisis was
defined as a painful episode lasting longer
than 24 h. Frequencies of CVA, aseptic ne-
crosis and priapism were also determined
before and during HU administration. The
diameters of leg ulcers were evaluated every
month throughout the study.
Statistical analysis
The paired t-test or Wilcoxon test was
used to compare the differences between
initial and final measurements and the dif-
ferences between the mean values obtained
for different HU doses (18,19), depending
on sample distribution. The Spearman corre-
lation coefficient was used to determine bi-
variate associations between defined vari-
ables (19).
Results
Patients
Eight patients with sickle cell anemia
(five men and three women) and two pa-
tients with Sß thalassemia (one man and one
woman) were enrolled in the study in De-
cember 1993. The globin gene haplotypes
among sickle cell anemia patients were BEN/
CAR in five patients, CAR/CAR in two, and
BEN/BEN in only one, and among Sß thalas-
semia patients, BEN in one and CAR in the
other (Table 1).
HU was introduced due to severe painful
Table 1 - Clinical and laboratory characteristics of sickle cell patients undergoing hydroxyurea (HU) treatment.
Patient Gender Age (year) α Thalassemia Haplotype Femoral Cholelithiasis HU HU
head eligibility follow up
SS Sß necrosis (month)
1 male 20  BEN/BEN + + CVA 19
2 male 22 + BEN/CAR +  CVA 26
3 male 20  BEN/CAR   priapism 12
4 male 33  CAR/CAR  + priapism 6
5 male 20  CAR/CAR   leg ulcer 7
6 female 30  BEN/CAR   leg ulcer + Hb <6 g/dl 7
7 female 24  BEN/CAR   leg ulcer 8
8 female 20  BEN/CAR  + leg ulcer + pain crisis 6
9 female 35 BEN/ ... +  leg ulcer 6
10 male 20 CAR/ ...  + pain crisis 15
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crises in two patients, Hb concentration lower
than 6 g/dl in three, priapism in two, CVA in
two patients, and extensive leg ulcers in five.
Four of the patients fulfilled more than one
of the criteria required to enter the study.
The ages ranged from 20 to 44 years (mean ±
SD: 24.0 ± 5.9; median: 21.0). Patients were
treated for a period of 6 to 19 months (mean:
11.2 ± 6.8; median: 21.0). Four patients were
treated for 12 months or longer, one for 8
months, two for 7 months and three for 6
months. The initial HU dose was 15 mg kg-1
day-1 for two patients with low weight (less
than 50 kg). At the end of the study (October,
1995), the examination of HU doses revealed
that five patients received the maximal doses
(20 mg kg-1 day-1) and the remaining five
patients received 15 mg kg-1 day-1 doses of
HU (Table 2).
Changes in Hb, Hb F and MCV
The Hb concentrations increased signifi-
cantly when compared with the initial values
(P<0.01). The increase ranged from 0.7 to
2.0 g/dl (mean ± SD: 1.3 ± 0.5; median: 1.2).
In one of these patients (patient No. 1), the
Hb concentration repeatedly exceeded 12.5
g/dl during the administration of 20 mg kg-1
day-1 HU. Although no morbidity was asso-
ciated with this high Hb concentration, the
HU dose was decreased to 15 mg kg-1 day-1.
Two patients were excluded from the analy-
sis because they had received packed red cell
transfusions at the beginning of the study.
The difference between mean Hb concentra-
tions obtained during the administration of
10 and 15 mg kg-1 day-1 HU (P<0.05) was
significantly greater than the difference be-
Table 2 - Hemoglobin (Hb (g/dl)) and fetal hemoglobin (Hb F (%)) before
and after hydroxyurea (HU) administration.
Final doses of HU are also shown. *Cerebral vascular accident in
transfusion.
Hb (g/dl) Hb F (%) Final dose of HU
(mg kg-1 day-1)
Before After Before After
Patient 1 10.6* 11.9 2.8 14.5 15
Patient 2 9.4* 10.8 0.7 18.5 20
Patient 3 4.8 6.8 6.3 15.9 20
Patient 4 7.7 8.7 2.5 6.0 15
Patient 5 7.6 9.1 4.1 10.7 20
Patient 6 5.4 6.6 2.3 8.9 15
Patient 7 6.0 6.7 2.7 6.2 20
Patient 8 6.9 8.5 2.1 3.9 20
Patient 9 8.0 9.6 7.5 19.2 15
Patient 10 10.6 11.4 3.7 17.8 15
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Figure 1 - Effect of different doses of hydroxyurea (HU) on mean values of hemoglobin (Hb), fetal hemoglobin (Hb F) and mean corpuscular volume
(MCV) for 8 patients with sickle cell anemia (patients 1-8) and 2 patients with Sß thalassemia (patients 9 and 10).
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tween mean Hb concentrations obtained dur-
ing the administration of 15 and 20 mg kg-1
day-1 HU (P = 0.60). These results are shown
in Figure 1.
In all patients the Hb F concentration
increased significantly when compared with
the initial value (P<0.01), ranging from 1.0
to 18.1% (mean ± SD: 7.7 ± 5.3; median:
7.0). The mean Hb F concentrations ob-
tained during the administration of 15 mg
kg-1 day-1 HU were significantly higher than
those obtained during the administration of
10 mg kg-1 day-1 (P<0.01). However, they
were significantly lower (P<0.01) than those
obtained during administration of 20 mg
kg-1 day-1 HU. These results are shown in
Figure 1. The response of Hb F to HU was
not associated with gender or ß-globin hap-
lotype.
In eight of ten patients the final MCV
values increased significantly when com-
pared with the initial values (P = 0.01). This
increase ranged from 11-28 fl (femtoliters)
(mean ± SD: 17.4 ± 5.8; median: 17.0). The
mean MCV values obtained during the ad-
ministration of 15 mg kg-1 day-1 HU were
significantly higher than those obtained dur-
ing the administration of 10 mg kg-1 day-1
(P<0.01). However, they were significantly
lower than those obtained during the admin-
istration of 20 mg kg-1 day-1 HU (P<0.01).
These results are shown in Figure 1.
There was no correlation between the
increase of Hb and Hb F (r = -0.26; P = 0.46)
or the MCV values (r = -0.23; P = 0.53),
while the increase in MCV and Hb F concen-
tration (r = 0.67; P = 0.03) was highly corre-
lated.
Toxicity
In all patients, the final reticulocyte counts
were significantly lower than the initial ones
(P<0.01). This decrease ranged from 51 x
109/l to 205 x 109/l (mean ± SD: 128.0 ± 70.0
x 109; median: 98.0 x 109). Since the reticu-
locyte count for one of the patients was
performed after the beginning of the study,
the patient was excluded from this analysis.
The mean reticulocyte values obtained dur-
ing the administration of 15 mg kg-1 day-1
HU were significantly lower than those ob-
tained during the administration of 10 mg kg-1
day-1 (P<0.05). The same significant differ-
ences were observed between the values
obtained during the administration of 20 and
15 mg kg-1 day-1 HU (P<0.05). These results
are shown in Figure 2. The decrease in reticu-
locyte counts during treatment was not cor-
related with the increase in Hb concentration
(r = 0.02; P = 0.095) or with the decrease in
neutrophil counts (r = 0.031; P = 0.46).
The highest decrease of neutrophil counts
was 9.5 x 109/l and the lowest decrease 1.3 x
109/l (mean ± SD: 3.8 ± 2.7; median: 3.0). In
eight of ten patients the mean neutrophil
values obtained during the administration of
15 mg kg-1 day-1 HU were lower than those
obtained during the administration of 10 mg
kg-1 day-1 (P<0.02). The final neutrophil
counts were significantly lower than the ini-
tial values (P<0.01) but in two patients they
were higher than or similar to the initial
counts. Significant differences were also
observed among values obtained during the
administration of 20 and 15 mg kg-1 day-1
HU (P<0.01). These results are shown in
Figure 2. Platelet counts did not change sig-
nificantly during the study (Figure 2). No
hematologic, hepatic or renal toxicity was
observed in any of the ten patients.
Clinical responses
The mean annual frequency of severe
pain crises before HU administration was
1.3 (range: 0.0 to 6.0), and decreased to 0.6
(range: 0.0 to 4.0) during HU treatment.
Although an improvement in frequency and
severity of pain crises was reported by all
patients, no significant differences in annual
frequency were demonstrable, due to the
small number of patients with pain crises
enrolled in this study. However, one patient
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who presented moderate to severe crises at
least every two months had no crisis during
HU administration. During the study period
there was no recurrence of CVA in the two
patients who had suffered a previous stroke.
There was a recurrence of priapism in one of
the two patients who had priapism previ-
ously, but the second episode was not as
severe as the first one. Reduction in the
diameter of leg ulcers was not observed in
any patient.
Discussion
Hydroxyurea increases fetal hemoglobin
production and improves the clinical course
of sickle cell disease (1,4-12), but the ad-
equate dose for each patient varies widely.
In the present study, maximum Hb concen-
tration was obtained in most patients with an
intermediate dose of HU (15 mg kg-1 day-1).
The Hb concentration obtained with this
dose was significantly higher than that ob-
tained with 10 mg kg-1 day-1. No significant
difference was observed in Hb levels when
the dose was raised to 20 mg kg-1 day-1.
Although the number of patients was small,
these results suggest that 15 mg kg-1 day-1
HU is sufficient to improve Hb concentra-
tion. Previous studies (5,7) determined the
maximum doses of HU tolerated but not the
minimum efficient dose as done in the pres-
ent study. Moreover, to our knowledge, there
are no studies on the use of HU in Brazilian
patients with sickle cell disease.
During the increase of the dose of HU
from 10 to 20 mg kg-1 day-1 there was an
increase in Hb F concentration and a de-
crease in reticulocyte counts, as described
previously (5,7,10-12). However, these find-
ings did not significantly correlate with the
increase in Hb concentration. Despite the
risks of hemoglobin increase without a con-
comitant increase in fetal hemoglobin which
could represent a higher risk of sickling,
patient No. 1, who showed a concentration
of Hb higher than 12.5 g/dl, did not have any
vasoocclusive episode during the study. How-
ever, we decided to reduce his HU dose. It is
well known that red cell survival increases
during HU therapy (4,5,13,20).
In the present study, the increase in Hb F
was not related to gender, probably due to
the reduced number of patients enrolled, or
to ß-globin haplotypes, since most patients
were heterozygous for BEN/CAR haplotypes.
An evident result of HU treatment was
the increase in MCV. Improvement in red
Figure 2 - Effect of different doses of hydroxyurea (HU) on mean reticulocyte, neutrophil, and platelet counts for 8 patients with sickle cell anemia
(patients 1-8) and 2 patients with Sß thalassemia (patients 9 and 10).
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cell diameter was correlated with the in-
crease in HU dose, as observed previously
(4,5,7). The increase in MCV during HU
treatment is primarily due to an increase in
cell Hb content but may also reflect altered
properties of red cell membranes or the in-
crease in the water content of red cells
(2,7,14).
Although hydroxyurea has been used in
patients with CVA, there are reports of re-
currence and death when transfusion treat-
ment is stopped and followed by treatment
with hydroxyurea only (10). In the present
study, we started HU treatment in two pa-
tients who presented one episode of stroke
during childhood and who had been receiv-
ing transfusion treatment for at least twelve
years. One of them was also receiving
deferoxamine. The decision to start with HU
in these cases was based on the fact that both
patients had developed alloimmunization
which prevented transfusion and one of them
had a very difficult vein access. No recur-
rence of stroke occurred in either case during
the study.
The frequency and severity of vasoocclu-
sive crises appeared to decrease in all pa-
tients, in accordance with other reports
(5,7,12). However, no significant differences
in annual frequency were demonstrable, prob-
ably due to the reduced number of patients
with pain crises.
Although a decrease in reticulocyte and
neutrophil counts was observed in most of
the patients, critical values were not reached
in any of them. None of the patients presented
hepatic or renal toxicity or an increase in
infection frequency during HU treatment.
The present results suggest that a consid-
erable proportion of patients obtained an
improvement in Hb and Hb F concentration
and MCV values during HU administration
and that a 15 mg kg-1 day-1 dose of HU
appeared to be adequate for sickle cell dis-
ease patients, considering positive responses
and minimal side effects, and indicate that a
larger number of patients should be evalu-
ated using lower doses of HU.
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